Astellas Pharma S.A.S. clinical trials

A country office of Astellas Pharma Inc

The registry lists 4 studies whose lead sponsor is Astellas Pharma S.A.S.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 1, 2024.

Studies

Recruiting first, then most recently updated. Showing 4 of 4. All Astellas Pharma Inc studies →

• A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)CompletedNCT02147938

  Sponsor listed in the registry: Astellas Pharma S.A.S.

• A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation YearCompletedNCT02143479

  Sponsor listed in the registry: Astellas Pharma S.A.S.

• Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematologyCompletedNCT02127788

  Sponsor listed in the registry: Astellas Pharma S.A.S.

• Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These PatientsCompletedNCT02214771

  Sponsor listed in the registry: Astellas Pharma S.A.S.